You just read:

Combination treatment (Pr)Tafinlar® (dabrafenib) plus (Pr)Mekinist® (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy(1)

News provided by

Novartis Pharmaceuticals Canada Inc.

Jun 15, 2017, 05:59 ET